Breaking News
September 22, 2018 - Cardiac MR With Contrast Feasible in Developing World
September 22, 2018 - Daily low-dose aspirin doesn’t reduce heart-attack risk in healthy people
September 21, 2018 - Children with asthma found to be disadvantaged in education and future occupation
September 21, 2018 - Interaction of chemical slurry and ancient shale in fracking wastewater causes radioactivity
September 21, 2018 - Researchers find that sample size is key factor determining accuracy of study results
September 21, 2018 - Study shows how the drive to eat overpowers the brain’s signal to stop
September 21, 2018 - 30 Million Americans Now Have Diabetes
September 21, 2018 - Thousands of breast cancer gene variants engineered and analyzed
September 21, 2018 - The current fellowship interview process is cumbersome — Stanford researchers have a better idea
September 21, 2018 - Progenitor cells for human bone and cartilage have been identified
September 21, 2018 - Study reveals new therapeutic target for pediatric tumor-associated intractable epilepsy
September 21, 2018 - SLU’s College professor receives NIH grant to develop I-TEST project
September 21, 2018 - DermTech completes enrollment in clinical study to assess DNA damage and reversal
September 21, 2018 - Grieving patients treated with talk therapy have lower risk of suicide and psychiatric illness
September 21, 2018 - NIH and FDA call for eliminating involvement of RAC in human gene therapy experiments
September 21, 2018 - New system uses algorithm to convert 2D videos into 3D printed ‘motion sculptures’
September 21, 2018 - Sea squirt model reveals key molecules in dopaminergic neuron differentiation
September 21, 2018 - Effective management of neonatal abstinence syndrome requires coordinated ‘cascade of care’
September 21, 2018 - Refugees seek care for wounds of war
September 21, 2018 - Under the sea, in an octopus’ garden on ecstacy
September 21, 2018 - Eating foods with low nutritional quality ratings linked to cancer risk in large European cohort
September 21, 2018 - Giving kids honest information about water consumption may help them make healthy choices
September 21, 2018 - Horwitz Prize Awarded for Work on Hormones
September 21, 2018 - CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients
September 21, 2018 - Scientists discover new molecules that work together to remove unwanted DNA
September 21, 2018 - Dr. Fenella France to deliver 2019 Plenary Lecture
September 21, 2018 - New research finds that MHC-II molecules have more influence on tumors than MHC-I
September 21, 2018 - Researchers study effects of cardiac cycle in simple learning task
September 21, 2018 - FDA takes new steps to address opioid crisis by approving Opioid Analgesic Risk Evaluation and Mitigation Strategy
September 21, 2018 - Positive Barhemsys Phase 3 Treatment Data Published in Anesthesia & Analgesia
September 21, 2018 - Celiac Disease Screening: MedlinePlus Lab Test Information
September 21, 2018 - Autism linked to egg cells’ difficulty creating large proteins
September 21, 2018 - Tweaking nuclear pores could provide new avenue to battle against cancer
September 21, 2018 - Experts warn health care providers to slow down in allowing smart pill in patient care settings
September 21, 2018 - MoreGrasp reports breakthrough development of grasp neuroprosthetics activated by thought control
September 21, 2018 - Study reveals new way to target HER2-negative metastatic breast cancer
September 21, 2018 - CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL
September 21, 2018 - Study offers solid link between visceral organs and brain’s reward, motivation system
September 21, 2018 - First U.S. patient treated with innovative gene therapy at Bascom Palmer Eye Institute
September 21, 2018 - New study shows how Ethiopia has managed to achieve extraordinary progress
September 21, 2018 - Choroidal Detachment – The American Society of Retina Specialists
September 21, 2018 - New clinical trial evaluates aesthetic results of conservative surgery in breast cancer
September 21, 2018 - Discovery of a key protein involved in the development of autism
September 21, 2018 - Air pollution appears to be linked to increased risk of developing dementia
September 21, 2018 - Henry Ford Health System receives $600k grant to study genetic makeup of gliomas
September 21, 2018 - Arthritis common in individuals with varying degrees of depression, finds study
September 21, 2018 - Scientist intends to fight pathogenic bacteria with viruses
September 21, 2018 - New research suggests link between PFAS chemicals and hyperthyroidism in pet cats
September 21, 2018 - Multi-year study data shows impact of new soft contact lens to slow myopia progression in children
September 21, 2018 - Neuroscientists identify circuit for brain’s statistical inference about motion
September 21, 2018 - MILabs’ VECTor6 system wins Commercial Innovation Award at WMIC 2018
September 21, 2018 - Scientists find wild African monkeys infected with bacterium that causes syphilis, yaws in humans
September 21, 2018 - 2006 to 2015 Saw Increase in Severe Maternal Morbidity
September 21, 2018 - Similar changes in the brains of patients with ADHD and emotional instability
September 21, 2018 - Cobalt mining in DR Congo takes a high toll on both creuseurs and environment
September 21, 2018 - Eating fatty fish during pregnancy may boost unborn child’s brain development
September 21, 2018 - Study reveals promising new drug candidate to treat acute renal failure
September 21, 2018 - Neural signal that urges to eat overpowers the one that says to stop
September 21, 2018 - Scientists achieve breakthrough in accelerated diagnosis of multi-resistant hospital pathogens
September 21, 2018 - Researchers simulate how different breast tissues respond to heat from MRIs
September 21, 2018 - Despite red flags at surgery centers, overseers award gold seals
September 21, 2018 - Zapping Airway Nerves May Help COPD Patients Breathe
September 21, 2018 - Researchers find answers as to why some people are at risk of gout
September 21, 2018 - Stars of Stanford Medicine: Genetic counseling and compassion
September 21, 2018 - Researchers use reinforcement learning to train gliders to soar like birds
September 21, 2018 - New federally-funded research project could lead to treatments that extend human lifespan
September 21, 2018 - Health insurance ads have shifted over time due to health plans offered via ACA
September 21, 2018 - Use of transcranial electrical stimulation to bolster creativity has far-reaching implications
September 21, 2018 - Scientists find way to boost efficacy of powerful antimalarial drug with anti-cancer medicines
September 21, 2018 - Weighing the risks and benefits of drug tapering—two patients, two perspectives
September 21, 2018 - The “exposome” revealed: a barrage of bacteria, chemicals, microscopic animals and more
September 21, 2018 - Top three immune boosting recommendations to ward off freshers’ flu
September 21, 2018 - Young children’s oral microbiota could serve as early indicator for obesity
September 21, 2018 - Older individuals with multiple sclerosis report higher quality of life than younger counterparts
September 21, 2018 - LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines
September 21, 2018 - AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
September 21, 2018 - Alzheimer’s drug may stop disease if used before symptoms develop
September 21, 2018 - Human skeletal stem cell can generate cartilage, bone
September 21, 2018 - UK and European research collaborations receive vote of confidence by three major cancer charities
September 21, 2018 - Microbiota in the intestines and cell stress cause colon cancer
Autoinjected Secukinumab a Hit in Psoriatic Arthritis

Autoinjected Secukinumab a Hit in Psoriatic Arthritis

image_pdfDownload PDFimage_print

Action Points

  • Note that this randomized study found that the Il-17a inhibitor secukinumab was efficacious in improving symptoms among patients with psoriatic arthritis.
  • Be aware that the medication fared best among those who had not previously been treated with an anti-TNF agent. Higher doses may be needed for those who were previously exposed.

The interleukin (IL)-17A inhibitor secukinumab (Cosentyx) provided durable benefits in the treatment of psoriatic arthritis, and patient satisfaction with self-administration using an autoinjector was high, researchers found.

At week 24 in a phase III trial known as FUTURE 3, improvements of at least 20% on the criteria of the American College of Rheumatology (ACR20) were seen in 48.2% of patients receiving 300 mg of secukinumab every 4 weeks and in 42% of those receiving 150 mg, compared with 16.1% of those given placebo (P<0.0001), according to Peter Nash, MD, of the University of Queensland in Brisbane, Australia, and colleagues.

Week 24 was the end of the placebo-controlled phase of the study. By week 52, when all patients were receiving the active treatment, ACR20 response rates rose to 58.3% and 47.1% in the 300- and 150-mg groups, respectively.

And at least 88% of patients said that they were satisfied or very satisfied with the autoinjector, finding it easy or very easy to use, the researchers reported in Arthritis Research & Therapy.

The efficacy findings confirm what has previously been seen in other phase III trials of subcutaneous secukinumab. For example, in a study known as FUTURE 1, published in 2015 in the New England Journal of Medicine, ACR20 responses at week 24 were observed in 50% of patients receiving 150 mg monthly and in 50.5% of those receiving 75 mg. In FUTURE 2, published the same year in The Lancet, 54% of patients receiving 300 mg had ACR20 responses at week 24, as did 51% of those given 150 mg.

FUTURE 3 is an ongoing randomized trial being conducted at 74 centers worldwide. Participants have active disease, defined as at least three tender and swollen joints, and could have previously received up to three tumor necrosis factor (TNF) inhibitors.

A total of 414 patients were enrolled. Mean age was 50, slightly more than half were women, and more than 90% were white. Mean time since the diagnosis of psoriatic arthritis ranged from 6.6 to 8.3 years, and one-third had previously received a TNF inhibitor. Mean number of tender and swollen joints were 21 and 10, respectively.

Almost half were using methotrexate at baseline.

In general, patients who were anti-TNF naive fared better. At week 24, the ACR20 and ACR50 responses among patients who were anti-TNF naive were 51.6% and 45.7% in the 300 mg and 150 mg groups, respectively, while in patients who had previously had an inadequate response to anti-TNF treatment, the response rates in the two dosage groups were 40.9% and 34.1%.

The greater responses seen with the higher dose among patients with previous anti-TNF exposure suggests that the 300 mg dose is appropriate for these refractory patients, the authors indicated.

On the Psoriasis Area and Severity Index (PASI), improvements of 75% were seen in 61.3% and 55.9% of the 300- and 150-mg groups at week 24, compared with 11.9% of the placebo group. At week 52, PASI75 responses were seen in 74.2% of the 300-mg group and in 60.3% of the 150-mg group.

On the Health Assessment Questionnaire-Disability Index (HAQ-DI) changes from baseline at week 24 were -0.38 in the 300-mg group and -0.27 in the 150-mg group compared with -0.17 in the placebo group, and mean changes in pain scores were -18.23 and-12.46 versus -3.75. At week 52, changes from baseline on the HAQ-DI were -0.43 and -0.30 in the 300 mg and 150 mg groups, while changes in pain scores were -20.3 and -11.8.

During the 52 weeks, the incidence rates of adverse events were 194.9 and 192.5 per 100 patient-years, while the rates of serious adverse events were 8.8 and 10.2 per 100. Two deaths occurred — one pancreatic cancer and one small cell lung cancer.

Candida infections were an adverse event of special interest, because IL-17 plays a crucial role in mucocutaneous defense against fungal and bacterial infections. Oral candidiasis was reported in three patients in the 300-mg group and five patients in the 150-mg group, and two patients in each dose group experienced vulvovaginal candidiasis. Patients on secukinumab should be observed closely for Candida infections, the researchers noted.

Neutropenia developed in two patients in the 150-mg group and one patient in the 300-mg group.

“In summary, self-administration of subcutaneous secukinumab provided sustained improvements at 52 weeks across multiple clinical domains in patients with active psoriatic arthritis,” Nash and colleagues concluded, adding that patients were satisfied with the autoinjector device.

A limitation of the study was the lack of a placebo control after week 24.

The study was funded by Novartis Pharma.

The authors reported financial relationships with Novartis, AbbVie, Roche, Pfizer, Bristol-Myers Squibb, Janssen, Celgene, Crescendo Bioscience, Genentech, Eli Lilly, Merck, UCB, and Amgen. Several are employees of Novartis.

2018-03-16T15:30:00-0400

Tagged with:

About author

Related Articles